Trastuzumab Pamirtecan Delivers Unprecedented Response Rates in Recurrent Endometrial Cancer: Key Data from BioNTech and DualityBio
Largest-Ever Cohort Reports Objective Response Rate Over 47% Across HER2 Levels
If you’re following breakthroughs in cancer therapy, BioNTech (BNTX) and DualityBio have just released Phase 2 trial data that could change the treatment landscape for advanced endometrial cancer. Their antibody-drug conjugate, trastuzumab pamirtecan, achieved a confirmed objective response rate (ORR) as high as 49.3% in heavily treated patients—significantly surpassing the typical 15% response rate seen with standard chemotherapy, especially for those with lower HER2 expression.
Key Efficacy Data Highlights: Strong Response Regardless of HER2 Level or Prior Treatments
This global Phase 2 study enrolled 145 patients with recurrent or advanced HER2-expressing endometrial cancer whose disease had progressed after first-line therapy. The trial, the largest of its kind for a HER2-targeted drug in this cancer, reported standout efficacy—particularly important for a disease with worsening mortality trends and few effective options for those with lower HER2 levels.
| Population | Confirmed ORR (%) | Median PFS (months) | Median DoR (months) |
|---|---|---|---|
| All centrally-tested (n=96) | 47.90 | 8.10 | 10.30 |
| Checkpoint inhibitor prior therapy (n=73) | 49.30 | – | – |
| All local-testing (n=143) | 44.10 | 8.00 | 10.30 |
| IHC1+ (low HER2) | 33.90 | – | – |
| IHC2+ (moderate HER2) | 40.40 | – | – |
| IHC3+ (high HER2) | 73.10 | – | – |
Note: Median PFS = progression-free survival, DoR = duration of response; dashes indicate data not explicitly provided in this subgroup.
Efficacy Strong for Patients After Immune Therapy—Including Those with Lower HER2 Expression
Among patients with confirmed HER2 status and prior immune checkpoint inhibitor therapy, the drug reached a 49.3% response rate. Even in those with low (IHC1+) and moderate (IHC2+) HER2 expression—historically a difficult-to-treat group—ORRs were 33.9% and 40.4%, respectively. For the highest expressing group (IHC3+), a remarkable 73.1% response rate was achieved.
Median progression-free survival (PFS) hovered around 8 months for all evaluable groups, and the median duration of response reached 10.3 months. These numbers are notable, especially when compared with the much lower historic benchmarks of existing therapies.
Safety Profile Remains Manageable—and in Line with Expectations
Safety data indicated that trastuzumab pamirtecan’s side effect profile was largely consistent with other HER2-targeted ADCs. Most adverse events (nausea, anemia, decreased platelets, and fatigue) were mild. Grade 3 or higher adverse effects were observed in 46.9% of patients, with serious lung-related events in under 5%—a risk profile considered manageable in the context of advanced cancer treatments. The majority of issues were effectively addressed with standard medical interventions.
Regulatory Acceleration Charts New Path Forward
Recognizing its potential, the FDA has already granted trastuzumab pamirtecan Fast Track and Breakthrough Therapy designations for endometrial cancer. An international Phase 3 trial is ongoing and could further solidify the case for regulatory approval. BioNTech and DualityBio plan to file for a biologics license in 2026, pending additional data and regulatory feedback.
Takeaway: Could Trastuzumab Pamirtecan Redefine Endometrial Cancer Care?
This new data marks a potential paradigm shift for HER2-expressing endometrial cancer, especially for patients who have already tried—and failed—multiple lines of therapy. The ability to deliver meaningful responses even in those with low HER2 levels or following prior immune therapy broadens clinical possibilities.
While larger and longer-term studies are warranted, these results put all eyes on BioNTech’s upcoming Phase 3 readouts and future regulatory milestones. For both researchers and investors, the next chapters in this ADC’s development are well worth watching.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI